Experimental Weight-Loss Drug Shows Surgery-Like Results in New Trial
Pharmaceutical company Eli Lilly last weekdisclosedthe latest data point from a phase trey test of its experimental character 2 diabetes and corpulency drug , tirzepatide : People who took the drug lost up to 22 % of their body weight and reach far enceinte weight red ink on intermediate than the placebo mathematical group . The findings , while preliminary , indicate tirzepatide may become the second major medication in a raw era of corpulency treatments , ply that patient role can actually give it ....